Thiard News@F4F

@newsen.bsky.social

5 days ago

Vivatides Therapeutics Secures $54 Million for RNA Therapeutics Development Vivatides Therapeutics has successfully closed an oversubscribed $54 million Series A financing to further develop their revolutionary RNA-targeting therapeutics.

Vivatides Therapeutics Secures $54 Million for RNA Therapeutics Development #China #Suzhou #RNA_Therapeutics #Qiming_Venture_Partners #Vivatides_Therapeutics

Martin Sauvageau

@martinsauvageau.bsky.social

4 weeks ago

Excited to see this project get the underway. I am looking forward to working with Thomas Duchaine, @bcmagog.bsky.social & industry partners to develop new #RNA_Therapeutics targeting #splicing defects for neurological and tare diseases through our complementary biomanufacturing platforms.

Thiard News@F4F

@newsen.bsky.social

4 weeks ago

Ribo Presents Innovative Ex-Hepatic Delivery Data at RNA Leaders Europe Conference Suzhou Ribo Life Science is set to share groundbreaking data on ex-hepatic delivery technologies at the RNA Leaders Europe Conference, aimed at expanding siRNA applications.

Ribo Presents Innovative Ex-Hepatic Delivery Data at RNA Leaders Europe Conference #China #Suzhou #RNA_Therapeutics #Ribo_Life_Science #siRNA_Technology

Thiard News@F4F

@newsen.bsky.social

1 month ago

Avidity Biosciences to Present Groundbreaking Research at 2026 MDA Conference Avidity Biosciences is set to showcase innovative findings on RNA therapeutics at the 2026 MDA Conference, demonstrating its commitment to addressing muscular dystrophies.

Avidity Biosciences to Present Groundbreaking Research at 2026 MDA Conference #USA #Orlando #RNA_Therapeutics #Avidity_Biosciences #Duchenne_Muscular_Dystrophy

Thiard News@F4F

@newsen.bsky.social

3 months ago

Upcoming Webinar Reveals Strategies for RNA Drug Candidate Detection and Characterization Join the upcoming Xtalks webinar to explore innovative techniques for detecting and characterizing RNA drug candidates to enhance therapeutic development.

Upcoming Webinar Reveals Strategies for RNA Drug Candidate Detection and Characterization #USA #Toronto #Drug_Development #RNA_Therapeutics #Xtalks

Thiard News@F4F

@newsen.bsky.social

5 months ago

Avidity Biosciences Announces Q3 2025 Financials and Novartis Acquisition Plans Avidity Biosciences shares its financial results for Q3 2025, highlighting its merger with Novartis and the promising development of RNA therapeutics.

Avidity Biosciences Announces Q3 2025 Financials and Novartis Acquisition Plans #USA #San_Diego #RNA_Therapeutics #Novartis #Avidity_Biosciences

Thiard News@F4F

@newsen.bsky.social

5 months ago

Avidity Biosciences to be Acquired by Novartis in Major Deal Worth $12 Billion In a significant move in the biopharmaceutical sector, Novartis AG will acquire Avidity Biosciences for $12 billion. The merger emphasizes RNA therapeutics innovation and promises future advancements.

Avidity Biosciences to be Acquired by Novartis in Major Deal Worth $12 Billion #United_States #San_Diego #RNA_Therapeutics #Novartis #Avidity_Biosciences

Thiard News@F4F

@newsen.bsky.social

6 months ago

Innovative Long RNA Manufacturing for Next-Generation RNA Medicines: Join Xtalks Webinar Discover cutting-edge long RNA manufacturing techniques at the upcoming Xtalks webinar. Learn about new methods to advance RNA therapeutics.

Innovative Long RNA Manufacturing for Next-Generation RNA Medicines: Join Xtalks Webinar #Canada #Toronto #RNA_Therapeutics #Xtalks #Long_RNA

Thiard News@F4F

@newsen.bsky.social

7 months ago

Avidity Biosciences Closes Its Upsized Public Stock Offering to Fuel Growth in RNA Therapeutics Avidity Biosciences has finalized a significant public offering of common stock, raising $690 million to support its RNA therapeutic development programs and commercial expansion.

Avidity Biosciences Closes Its Upsized Public Stock Offering to Fuel Growth in RNA Therapeutics #United_States #San_Diego #stock_offering #RNA_Therapeutics #Avidity_Biosciences

Thiard News@F4F

@newsen.bsky.social

7 months ago

Avidity Biosciences Unveils Public Offering of Common Stock to Expand RNA Therapeutic Pipeline Avidity Biosciences announces an upsized public offering of common stock, intending to bolster its RNA therapeutics pipeline with significant proceeds.

Avidity Biosciences Unveils Public Offering of Common Stock to Expand RNA Therapeutic Pipeline #United_States #San_Diego #RNA_Therapeutics #Avidity_Biosciences #Antibody_Oligonucleotide

Thiard News@F4F

@newsen.bsky.social

7 months ago

Avidity Biosciences Plans Significant Public Offering for Expansion of RNA Therapeutics Avidity Biosciences has announced a proposed public offering of $500 million in shares to advance its RNA therapeutics development and commercial capabilities.

Avidity Biosciences Plans Significant Public Offering for Expansion of RNA Therapeutics #United_States #San_Diego #stock_offering #RNA_Therapeutics #Avidity_Biosciences

Thiard News@F4F

@newsen.bsky.social

7 months ago

Avidity Biosciences Set to Engage with Investors at Key Conferences in September Avidity Biosciences, Inc. announces its participation in multiple investor conferences in September 2025, showcasing their innovative RNA therapeutics.

Avidity Biosciences Set to Engage with Investors at Key Conferences in September #United_States #San_Diego #Investor_Conferences #RNA_Therapeutics #Avidity_Biosciences

Thiard News@F4F

@newsen.bsky.social

8 months ago

Avidity Biosciences Posts Strong Q2 2025 Results and Development Progress Avidity Biosciences announces its second-quarter 2025 financial results, showcasing significant progress in RNA therapy approvals and trials for neuromuscular diseases.

Avidity Biosciences Posts Strong Q2 2025 Results and Development Progress #USA #San_Diego #RNA_Therapeutics #Avidity_Biosciences #del-brax

Thiard News@F4F

@newsen.bsky.social

8 months ago

Exploring the Future of RNA-Based Therapeutics: Tsingke Biotech's Roundtable in Beijing Tsingke Biotech recently hosted the 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing, uniting top experts to discuss advances in RNA therapies and their delivery.

Exploring the Future of RNA-Based Therapeutics: Tsingke Biotech's Roundtable in Beijing #China #Beijing #RNA_Therapeutics #Tsingke_Biotech #Nucleic_Acid_Solutions

Thiard News@F4F

@newsen.bsky.social

10 months ago

TransCode Therapeutics Welcomes Dr. Phillip D. Zamore to Advisory Board TransCode Therapeutics has appointed Dr. Phillip D. Zamore to its Scientific Advisory Board, enhancing their RNA-targeted cancer therapy initiatives.

TransCode Therapeutics Welcomes Dr. Phillip D. Zamore to Advisory Board #無し #RNA_Therapeutics #TransCode #Dr._Zamore

Thiard News@F4F

@newsen.bsky.social

10 months ago

Avidity Biosciences Grants Inducement Awards to New Employees Avidity Biosciences has announced the granting of stock options and RSUs to new hires as part of its strategy to attract talent and innovate in RNA therapeutics.

Avidity Biosciences Grants Inducement Awards to New Employees #USA #San_Diego #RNA_Therapeutics #Avidity_Biosciences #AOCs

Thiard News@F4F

@newsen.bsky.social

11 months ago

Avidity Biosciences Reveals First Quarter 2025 Financial Performance and Key Developments Avidity Biosciences announces its first quarter 2025 financial results and outlines strategic plans, including regulatory updates and clinical trial progress.

Avidity Biosciences Reveals First Quarter 2025 Financial Performance and Key Developments #United_States #San_Diego #RNA_Therapeutics #Avidity_Biosciences #Del-zota

Thiard News@F4F

@newsen.bsky.social

11 months ago

Avidity Biosciences Grants Stock Options to New Employees Under Nasdaq Rule 5635(c)(4) Avidity Biosciences has granted substantial stock options to 33 new hires under the 2022 Employment Inducement Incentive Award Plan, boosting employee motivation.

Avidity Biosciences Grants Stock Options to New Employees Under Nasdaq Rule 5635(c)(4) #USA #San_Diego #stock_options #RNA_Therapeutics #Avidity_Biosciences

Thiard News@F4F

@newsen.bsky.social

1 year ago

TransCode Therapeutics Moves Forward with Phase 1 Clinical Trial for TTX-MC138 TransCode Therapeutics has announced the initial dosing of a patient in the fourth cohort of its Phase 1 trial for the TTX-MC138 therapy, aimed at treating metastatic cancer.

TransCode Therapeutics Moves Forward with Phase 1 Clinical Trial for TTX-MC138 #United_States #Boston #RNA_Therapeutics #TTX-MC138 #TransCode_Therapeutics

Thiard News@F4F

@newsen.bsky.social

1 year ago

TransCode Therapeutics Completes Direct Stock Offering, Enhancing Funding for Oncology Innovations TransCode Therapeutics has successfully closed a registered direct stock offering, raising $10 million for advancing RNA therapeutic research and development.

TransCode Therapeutics Completes Direct Stock Offering, Enhancing Funding for Oncology Innovations #USA #Boston #RNA_Therapeutics #TTX-MC138 #TransCode_Therapeutics

Thiard News@F4F

@newsen.bsky.social

1 year ago

Avidity Biosciences Issues Stock Options to New Hires Under Nasdaq Inducement Regulations Avidity Biosciences has announced stock option awards to new non-executive employees, as part of a strategic hiring initiative aligned with Nasdaq rules.

Avidity Biosciences Issues Stock Options to New Hires Under Nasdaq Inducement Regulations #USA #San_Diego #stock_options #RNA_Therapeutics #Avidity_Biosciences

Thiard News@F4F

@newsen.bsky.social

1 year ago

Versameb AG Achieves the First Patent in China for Signal Peptide Technology Versameb AG celebrates a key patent grant in China for its innovative signal peptide tech, enhancing RNA therapeutics. This milestone paves the way for advancements in medical treatments.

Versameb AG Achieves the First Patent in China for Signal Peptide Technology #Switzerland #RNA_Therapeutics #Basel #Versameb #signal_peptides

Thiard News@F4F

@newsen.bsky.social

1 year ago

Avidity Biosciences to Showcase RNA Therapeutics at MDA 2025 Conference Avidity Biosciences is set to present groundbreaking RNA therapeutic data at the 2025 MDA Conference, highlighting advances in neuromuscular disease treatments.

Avidity Biosciences to Showcase RNA Therapeutics at MDA 2025 Conference #USA #Dallas #RNA_Therapeutics #Avidity_Biosciences #MDA_Conference

Thiard News@F4F

@newsen.bsky.social

1 year ago

Avidity Biosciences Shares Promising Fourth Quarter 2024 Financial Results and Key Developments Avidity Biosciences announced its fourth quarter 2024 financial results, highlighting advancements in its rare neuromuscular disease programs and strong financial standing for 2025.

Avidity Biosciences Shares Promising Fourth Quarter 2024 Financial Results and Key Developments #USA #San_Diego #RNA_Therapeutics #Avidity_Biosciences #neuromuscular_diseases

Thiard News@F4F

@newsen.bsky.social

1 year ago

TransCode Therapeutics Holds Special Meeting to Discuss Key Proposals for Shareholders TransCode Therapeutics recently concluded a special meeting where shareholders voted on critical proposals regarding share issuance and meeting adjournments.

TransCode Therapeutics Holds Special Meeting to Discuss Key Proposals for Shareholders #United_States #Boston #RNA_Therapeutics #TransCode_Therapeutics #Nasdaq_RNAZ

Thiard News@F4F

@newsen.bsky.social

1 year ago

Avidity Biosciences Set to Showcase Innovations at Notable Investor Conferences Avidity Biosciences is poised to participate in significant healthcare investor conferences, presenting their pioneering RNA therapeutic developments including AOCs.

Avidity Biosciences Set to Showcase Innovations at Notable Investor Conferences #USA #San_Diego #RNA_Therapeutics #Avidity_Biosciences #AOCs

Thiard News@F4F

@newsen.bsky.social

1 year ago

Avidity Biosciences Implements Inducement Grants to Attract Talent in RNA Therapeutics Sector Avidity Biosciences has announced significant stock options and restricted stock units for new hires. These grants incentivize talent joining their innovative team in RNA therapeutics.

Avidity Biosciences Implements Inducement Grants to Attract Talent in RNA Therapeutics Sector #USA #San_Diego #RNA_Therapeutics #Avidity_Biosciences #Nasdaq_Grants

Thiard News@F4F

@newsen.bsky.social

1 year ago

TransCode Therapeutics Advances Clinical Trial with New Dose for TTX-MC138 in Patients TransCode Therapeutics has completed dosing in Cohort 3 of its Phase 1 clinical trial for TTX-MC138, showing promising early safety results and pharmacokinetic profiles.

TransCode Therapeutics Advances Clinical Trial with New Dose for TTX-MC138 in Patients #United_States #Boston #RNA_Therapeutics #TTX-MC138 #TransCode_RNAZ

Thiard News@F4F

@newsen.bsky.social

1 year ago

Avidity Biosciences Reveals New Stock Options for Employees Under Nasdaq Regulation Avidity Biosciences, Inc. has announced the granting of stock options and RSUs to a new employee in accordance with Nasdaq Listing Rule 5635(c)(4).

Avidity Biosciences Reveals New Stock Options for Employees Under Nasdaq Regulation #United_States #San_Diego #RNA_Therapeutics #Avidity_Biosciences #Antibody_Oligonucleotide_Conjugates

Thiard News@F4F

@newsen.bsky.social

1 year ago

Orna Therapeutics and Simnova Strengthen Alliance with New BCMA RNA Therapies Initiative Orna Therapeutics and Simnova expand their collaboration, focusing on BCMA-targeted RNA therapeutics, enhancing treatment options for multiple myeloma patients.

Orna Therapeutics and Simnova Strengthen Alliance with New BCMA RNA Therapies Initiative #USA #Cambridge #RNA_Therapeutics #Orna_Therapeutics #Simnova_Biotech